FDA grants priority review to Merck’s KEYTRUDA and KEYTRUDA QLEX combos with Padcev for muscle-invasive bladder cancer

The submissions are supported by data from the Phase 3 KEYNOTE-905 trial

Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer

Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population

RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr

RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation

Roche presents positive phase III data for vamikibart in uveitic macular edema

Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME

FDA approves Tezspire for chronic rhinosinusitis with nasal polyps

Approval broadens indication for Tezspire to a second disease characterized by epithelial-driven inflammation

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub

FDA approves Alembic’s Triamcinolone Acetonide injectable suspension USP, 40 mg/mL

Triamcinolone Acetonide injectable suspension USP is indicated for various autoimmune, inflammatory, and other conditions

Cupid achieves CE (EU IVDR) certification for pregnancy and syphilis test kits

Gujarat Themis Biosyn doubles fermentation production capacity at Vapi

With this expansion, the overall fermentation capacity of the company has increased from 450 KL to 990 KL